Ibrutinib
Using MRD to Determine Duration of Targeted Therapy Improves Outcomes in CLL
Overall survival (OS) can be improved in fit patients with chronic lymphocytic leukemia (CLL) if the minimal ...
JANUARY 12, 2024
Combining Inhibitors of BTK and BCL-2 Improves Outcome in R/R Mantle Cell Lymphoma
By combining ibrutinib and venetoclax, which are two targeted oral therapies with different mechanisms of action, a ...
DECEMBER 19, 2023
BTK Inhibitor Challenges Standard of Care in Younger Patients With MCL
Already widely considered a standard first-line treatment in older adults with mantle cell lymphoma (MCL), a Bruton ...
JANUARY 9, 2023
Study Identifies Cardiovascular Toxicities Associated With Ibrutinib
The study identified several cardiovascular toxicities associated with ibrutinib, including supraventricular ...
SEPTEMBER 26, 2019
Ibrutinib Bests Drug Combo in Older CLL Pts
San Diego—In older patients with newly diagnosed chronic lymphocytic leukemia (CLL), the BTK inhibitor ...
MARCH 4, 2019
FDA Approves Imbruvica With Gazyva for First-Line CLL Treatment
The labeling for ibrutinib (Imbruvica, Pharmacyclics/Janssen) has been expanded to include use with obinutuzumab ...
FEBRUARY 4, 2019
First-Line Ibrutinib-Based Rx More Effective, Less Toxic Than Standard for Younger CLL Patients
First-line treatment combining ibrutinib and rituximab (significantly improves progression-free survival and ...
JANUARY 14, 2019
Imbruvica Approved to Treat Waldenström Macroglobulinemia With Rituxan
The FDA approved the use of ibrutinib (Imbruvica, Pharmacyclics/Janssen) in combination with rituximab ...
AUGUST 30, 2018
FDA Approves Imbruvica to Treat Adults With Chronic GVHD
Imbruvica becomes the first and only therapy specifically approved for adults with cGVHD, a serious and ...
AUGUST 8, 2017
Anti-CD20 Therapy Boosts Efficacy of Ibrutinib in CLL
Chicago—When added to the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or ...
JULY 20, 2017
Jeff Sharman, MD, on Improving Response Rates in High-Risk CLL Patients
At the 2017 annual meeting of ASCO, Dr. Jeff Sharman, presented the findings of his study which suggests that ...
JUNE 6, 2017
Ibrutinib Controls Chronic GVHD After Steroids Fail
San Diego—After allogeneic hematopoietic cell transplantation (allo-HCT), ibrutinib provides durable control ...
APRIL 27, 2017
